(Q33993542)

30 July 2017

1 reference

title

Willingness to pay for a quality-adjusted life year: in search of a standard (English)

1 reference

30 July 2017

R A Hirth

1

1 reference

30 July 2017

M E Chernew

2

1 reference

30 July 2017

E Miller

3

1 reference

30 July 2017

A M Fendrick

4

1 reference

30 July 2017

W G Weissert

5

1 reference

30 July 2017

publication date

1 July 2000

1 reference

30 July 2017

published in

Medical Decision Making

1 reference

30 July 2017

volume

20

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

332-342

1 reference

Applications of cost-benefit analysis to health care. Departures from welfare economic theory.

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0272989X0002000310

Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X0002000310

Faecal occult blood screening for colorectal cancer: is it cost-effective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X0002000310

Cost-effectiveness of breast cancer screening: preliminary results of a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X0002000310

A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X0002000310

Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X0002000310

Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X0002000310

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X0002000310

The social contract and the treatment of permanent kidney failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X0002000310

Inconsistencies in the "Societal Perspective" on Costs of the Panel on Cost-Effectiveness in Health and Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X0002000310

Realistic rigor in cost-effectiveness methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X0002000310

•On the Role of Theory in Cost-Effectiveness Analysis- A Response to Garber, Russell, and Weinstein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X0002000310

Gender, firm size, industry, and estimates of the value-of-life

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X0002000310

The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X0002000310

Contingent Valuation: Is Some Number Better than No Number?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X0002000310

Whither scientific deliberation in health policy recommendations? Alice in the Wonderland of breast-cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X0002000310

Workplace Risks and the Value of Hazard Avoidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X0002000310

Cost-Effectiveness of Screening for Carotid Stenosis in Asymptomatic Persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X0002000310

10.1177/0272989X0002000310

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference